Navigation Links
Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
Date:5/23/2011

SINGAPORE, May 23, 2011 /PRNewswire/ -- Singapore company Novus Scientific Pte. Ltd announced that the TRAM Flap study (Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR® (100% Resorbable) vs Polypropylene (Permanent) Mesh) has passed the 20 patient mark, representing approximately one quarter of the 86 patient study compliment.

This groundbreaking multi-center, randomized trial involves University of California San Diego (UCSD) in the U.S. as well as National University Hospital and Tan Tock Seng Hospital in Singapore. Surgeons from all three study sites will be in attendance at IPRAS 2011, Vancouver, Canada, May 22nd-27th, 2011. Novus Scientific will also be present at IPRAS as an exhibitor at booth 808.

"We are very optimistic about the early results using TIGR® Matrix in this TRAM Flap study.  TIGR® Matrix may provide a good option to avoid long-term complications associated with permanent meshes and the high cost of using biological meshes."- James J. Chao, MD FACS, Study Investigator, Professor of Plastic Surgery and Orthopedic Surgery, University of California, San Diego (UCSD) Medical Centre, USA.

"We are proud to have reached this important milestone of the study and it was truly a great team effort by all study investigators in the 3 hospitals. Early results for TIGR® Matrix look excellent."- Associate Professor Thiam Chye Lim, Principal Investigator & Head of Division of Plastic, Reconstructive and Aesthetic Surgery, National University Hospital, Singapore.

"We're very pleased to be part of this important study and with how TIGR® Matrix feels and conforms to the donor site. So far, results are good and look very promising."- Dr. Marcus Wong, Study Investigator, Consultant and Section Head, Plastic, Reconstructive and Aesthetic Surgery, Tan Tock Seng Hospital, Singapore.

TIGR® Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. US FDA cleared TIGR® Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGR® Matrix Surgical Mesh throughout the United States, Canada, and Latin America.

TIGR® is a trademark of Novus Scientific Pte. Ltd

CONTACT:  

Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.com
James Archetto: +1-781-577-2599 - jim.archetto@novusscientific.com, both of Novus Scientific
www.novusscientific.com


'/>"/>
SOURCE Novus Scientific Pte. Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TIGR® Matrix Surgical Mesh - Exhibited Ahead of Anticipated CE Mark Approval at European Hernia Society 2011, Ghent, Belgium
2. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. National University Hospital Singapore Operates on Asias 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
4. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
5. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
6. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
7. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
8. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
9. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
10. Matrixx Initiatives, Inc. Announces End of Go-Shop Period
11. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):